Hugel has introduced a new line of hyaluronic acid (HA) fillers, targeting a market projected to grow to 14 trillion won.
On July 20, Hugel announced the launch of its new HA filler line, 'The Chaeum Signature.'
The new products consist of four types, each designed to be selected based on the treatment area and purpose. Typically, HA fillers undergo a crosslinking process to maintain a stable gel form of hyaluronic acid, which is easily broken down in the body.
The Chaeum Signature utilizes the proprietary 'MPC (Multi Purified Crosslinking)' technology from its affiliate, Acros. This method reportedly reduces the amount of crosslinking agent used by over 50% compared to traditional manufacturing processes while enhancing crosslinking efficiency with high-concentration HA materials.
Notably, a multi-purification process lasting about two weeks minimizes residual crosslinking agents (BDDE) and micro-hydrolysis byproducts (BDPE) that can occur during the crosslinking process, thereby enhancing safety and quality. The new line maintains the strong properties and durability of the existing 'The Chaeum Premium' line while reducing the use of crosslinking agents.
Jang Doo-hyun, CEO of Hugel, stated, "We are excited to present a differentiated product utilizing our proprietary MPC technology. We will continue to enhance product competitiveness and safety to build trust with medical professionals and consumers."
According to Fortune Business Insights, the global market for hyaluronic acid-based skin fillers was estimated at $4.83 billion (approximately 7.15 trillion won) last year. It is projected to grow at an annual rate of 8.10%, reaching $5.22 billion (about 7.7 trillion won) this year and expanding to $9.73 billion (around 14.4 trillion won) by 2034. The North American market accounted for approximately 42.93% of the total last year.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.